Headlands Technologies LLC Sells 8,331 Shares of LivaNova PLC (NASDAQ:LIVN)

Headlands Technologies LLC cut its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 39.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,971 shares of the company's stock after selling 8,331 shares during the quarter. Headlands Technologies LLC's holdings in LivaNova were worth $601,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of LivaNova by 12.7% during the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after acquiring an additional 265,291 shares during the last quarter. Point72 Asset Management L.P. grew its stake in LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after buying an additional 806,374 shares during the last quarter. Geode Capital Management LLC grew its stake in LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock valued at $70,676,000 after buying an additional 8,331 shares during the last quarter. Emerald Advisers LLC boosted its holdings in LivaNova by 8.2% during the fourth quarter. Emerald Advisers LLC now owns 752,540 shares of the company's stock valued at $34,850,000 after acquiring an additional 57,035 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of LivaNova by 17.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company's stock worth $32,678,000 after purchasing an additional 93,311 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Remove Ads

LivaNova Price Performance

NASDAQ LIVN traded down $0.46 during trading hours on Monday, reaching $35.49. 385,827 shares of the company's stock were exchanged, compared to its average volume of 614,002. The firm has a fifty day moving average of $43.47 and a 200-day moving average of $48.08. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a one year low of $33.43 and a one year high of $64.48. The stock has a market cap of $1.93 billion, a PE ratio of 84.21 and a beta of 0.90.

Wall Street Analyst Weigh In

LIVN has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 target price on shares of LivaNova in a report on Monday, March 17th. StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 25th. The Goldman Sachs Group cut their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Wolfe Research downgraded shares of LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Finally, Mizuho decreased their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.